CN107190013A
|
|
A kind of zika virus disease vaccine using people Ad5 replication-defective adenovirals as carrier
|
CN107034225A
|
|
Prepare the method that Ebola virus glycoproteins merge mutant with stromatin
|
CN107033242A
|
|
A kind of monoclonal antibody of anti-Ebola virus envelope glycoprotein in people source and application
|
CN107022007A
|
|
Antigen fragment, truncate and application based on Marburg virus envelope protein
|
CN108203458A
|
|
A kind of small peptide and its application
|
CN107267431A
|
|
Brucella 104M vaccine strains knock out recombinant bacterium and the application of VirB2 genes
|
CN107267432A
|
|
Brucella 104M vaccine strains knock out recombinant bacterium and the application of Per genes
|
CN107267430A
|
|
Brucella 104M vaccine strains knock out recombinant bacterium and the application of Omp25 genes
|
CN107153117A
|
|
A kind of predictive molecule for being used to judge targeting mab treatment tumor efficiency
|
CN105237640A
|
|
Anthrax toxin receptor CMG2 and human serum albumin fused protein
|
CN104940901A
|
|
ERRa and application of inhibitor of ERRa to interferon generation promotion and virus infection inhibition
|
CN105138715A
|
|
Microbial aerosol atmospheric diffusion hazard assessment method
|
CN104592385A
|
|
Fully humanized antibody for anti-bacillus anthracis PA antigen
|
CN104292331A
|
|
Humanized anti-human interferon (IFN) alpha antibody and application thereof
|
CN104098693A
|
|
Monoclonal antibody resistant to SasA (staphylococcus aureus surface protein A) antigen and application of monoclonal antibody
|
CN105233302A
|
|
Method for preparing influenza hemagglutinin glycoprotein polymer nanoparticles
|
CN105085652A
|
|
Platelet-derived growth factor-B mutant and preparation method and application thereof
|
CN105012322A
|
|
Application of sunset yellow in resisting Bacillus anthraci
|
CN103936856A
|
|
Antibody L4H7 with CD20-resistant antigen and application thereof
|
CN103897059A
|
|
Antibody L5H7 of anit-CD20 antigen and application of antibody L5H7
|